Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth ConferenceBusiness Wire • 08/07/24
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'Investors Business Daily • 08/07/24
Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/06/24
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating OverviewBusiness Wire • 08/06/24
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024Business Wire • 07/24/24
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in MedBusiness Wire • 07/18/24
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific MeetingBusiness Wire • 06/18/24
New Millie Report Finds Hybrid Maternal Healthcare Model Improve Deliveries, Patient Engagement and Cost SavingsBusiness Wire • 06/18/24
Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/07/24
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS TreatmentsSeeking Alpha • 06/06/24
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett SyndromeBusiness Wire • 05/15/24
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating OverviewBusiness Wire • 05/08/24
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 05/01/24
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling ScholarshipBusiness Wire • 04/29/24
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024Business Wire • 04/24/24